Investing in biosimilars makes sense as Pfizer needs new growth avenues. Pfizer's total revenue has fallen sharply in the last 5 years primarily due to the loss of patent protection of Lipitor, Viagra, Celebrex and some other drugs. In addition, we expect that much of the incremental revenue from new and pipeline drugs to be offset by continued declines in legacy drugs. Therefore, biosimilar investment makes sense, as estimates for the global market opportunity range from $10 billion to $35 billion for 2020.